(8 Total References)
Charles H. Wheatley III was ...
Charles H. Wheatley III was awarded the McDaniel Alumni Award for Professional Achievement at its annual awards banquet Oct. 16.
Wheatley graduated with honors from Western Maryland - now McDaniel - College as the college's first political science major and was awarded the Bates Prize for the most outstanding male graduating senior.
He was a member of the Argonauts, the college's honor society, and was involved with the men's glee club, theater performances and the student newspaper.
After graduating, he earned his J.D. degree with honors from the University of Maryland School of Law in 1959, where he was named to the Order of the Coif, the national law honor society, and was law clerk to the Maryland Court of Appeals.
He served as delegate to the Maryland General Assembly from 1962 to 1966 and as a delegate to the Maryland Constitutional Convention in 1967, as well as a member of the Baltimore City Council from 1971 to 1974.
As executive secretary of the Maryland State Teachers' Association from 1974 to 1978, he established a statewide legal services program for the State Bar Association and the State Teachers' Association.
He is currently co-director of the Learning Institute for Excellence.
Charles Wheatley, President, CEO of Cell Works, Inc.
The Company headquarters is located at 6200 Seafort Street (Freeport Center) Holabird Park, Baltimore, MD 21224
(Baltimore, MD) - February 3, 2002 - Cell Works Inc., an international biotech firm with headquarters in Baltimore, Maryland, announced the retirement of its President and Chief Operating Officer, Charles H. Wheatley, III, effective February 1, 2002.Wheatley had worked with the Company's predecessor since November 1996 and was named its first President and Chief Operating Officer in November 1997.His retirement announcement came as he had originally requested, following the completion of approximately five years of service. Prior to his work with Cell Works and its predecessor, Cell Gene, Wheatley earned his A.B. in Political Science from Western Maryland College and received the Order of the Coif, honors award while obtaining his J.D. from The University Maryland, School of Law.He
has had a broad record of experience and training that spanned over 40 years in law, business, government, and technology development and transfer, in medical, scientific, engineering, space automation and robotics.He served as a law clerk to the Maryland Court of Appeals, was elected to the Maryland General Assembly, the Baltimore City Council, the Maryland Constitutional Convention, a national Presidential Nominating Convention, the White House Conference on Small Business and various appointing commissions.Wheatley
presented seminars to the Department of Defense
, the National Security Agency
, the National Conference
of State Legislators, the American bar Association
, and numerous international manufacturers.He also served as the Executive Secretary of the Maryland State Teachers Association and the Chair of the Regional Manufacturing Institute.Wheatley
was named to Who's Who In the World, America, American Law, Science and Engineering, Finance and Industry, and Executives and Businesses.
sought to develop the public image of Cell Works
in many speaking presentations.He
was instrumental in securing the ComputerWorld - Smithsonian Innovation Award for the Company along with recognition in a featured story in the national magazine, Startup and numerous other publications.He
originated the present name for the Cell Works'
cancer circulating cell blood test, the BloodBiopsySM
During the period of his
assisted the Company in its startup, growing from three employees in portable buildings at UMBC, to its present staff of 30 at its modern laboratory and office facility.The Company, while collaborating in clinical studies with many prestigious medical institutions, has developed and validated several of its innovative cancer tests, receiving federal grants totaling approximately one and one-half million dollars to date from the National Institutes of Health
, the National Science Foundation
, and the Department of Defense
.Last year the National Cancer Institute
awarded Cell Works
a Small Business Innovation Research grant for pre-clinical development of LIV-1, the Company's breakthrough approach to treating liver cancer.This was followed by the prestigious and beneficial designation of "Orphan Drug" status by the United States Food and Drug Administration
Dr. Paul Ts'o, Chairman and Chief Executive Officer, under whom Wheatley
served said, "the Company is very thankful to him for his
valuable service and contribution during the last five years, particularly for the formation of the Company."Mr. Wheatley
has been asked by the Board of Directors to render additional assistance to Cell Works
on a part time basis for several ongoing projects as its Advisor On Corporate Relations.He
has recently moved to the family farm in Westminster where he
plans to provide consulting services at the facilities there in matters relating to the areas of law, health, government, education, real estate, insurance, and other domestic and international businesses. Wheatley
commented: "It was my pleasure to assist in the development of Cell Works
as a startup company.
Lack of money, space stymie biotech efforts - 2001-11-19 - Baltimore Business Journal
"Finding qualified employees depends on who you're looking for," said Charles H. Wheatley, president and chief operating officer for Cell Works (http://www.cell-works.com/)."Senior-level management can be hard to come by because the competition in the industry is so fierce.But you can get lower-level workers out of college." The BioTechnical Institute of Maryland
was created in 1997 to combat the region's lagging bioscience work force.Since then, the nonprofit organization in Baltimore has graduated 10 classes of about 12 students.Twenty-four different bioscience companies have hired graduates of the program.
Floyd Taub M.D. - on cover of TechGazette
"It provides a way of detecting, with fairly high conclusiveness," says Charles H. Wheatley, Cell Works' president and chief operating officer.
has so far funded its work with about $10 million in start-up capital raised from about 180 shareholders, according to Wheatley
They are targeting an initial public offering in 18 to 24 months, once production of the test is ramped up.
"We've already demonstrated A, that it works, B, there's a market, and C, you can do it," Wheatley